Ubs Group Ag Krystal Biotech, Inc. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 130,173 shares of KRYS stock, worth $26.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

130,173

Previous 97,240 33.87%

Holding current value

$26.8 Million

Previous $13.4 Million 71.92%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$134.94 - $176.75 $4.44 Million - $5.82 Million	32,933 Added 33.87%	130,173 $23 Million
Q2 2025 Aug 14, 2025	BUY	$123.36 - $181.0 $1.99 Million - $2.92 Million	16,121 Added 19.87%	97,240 $13.4 Million
Q1 2025 May 13, 2025	SELL	$142.64 - $194.44 $2.71 Million - $3.7 Million	-19,012 Reduced 18.99%	81,119 $14.6 Million
Q4 2024 Feb 14, 2025	BUY	$156.64 - $199.61 $9.99 Million - $12.7 Million	63,802 Added 175.62%	100,131 $15.7 Million
Q3 2024 Nov 14, 2024	BUY	$174.7 - $213.66 $1.36 Million - $1.66 Million	7,773 Added 27.22%	36,329 $6.61 Million

Q2 2024 Aug 13, 2024	SELL	$153.12 - $183.64 $3.44 Million - $4.13 Million	-22,472 Reduced 44.04%	28,556 $5.24 Million
Q1 2024 May 13, 2024	BUY	$108.01 - $179.35 $2.19 Million - $3.64 Million	20,268 Added 65.89%	51,028 $9.08 Million
Q4 2023 Feb 09, 2024	BUY	$96.0 - $128.29 $2.95 Million - $3.95 Million	30,760 New	30,760 $3.82 Million
Q2 2023 Aug 11, 2023	SELL	$78.48 - $130.32 $1.33 Million - $2.2 Million	-16,911 Reduced 60.12%	11,217 $1.32 Million
Q1 2023 May 12, 2023	SELL	$72.39 - $84.27 $1.05 Million - $1.22 Million	-14,495 Reduced 34.01%	28,128 $2.25 Million
Q4 2022 Feb 08, 2023	BUY	$63.14 - $79.9 $2.68 Million - $3.39 Million	42,459 Added 25889.63%	42,623 $3.38 Million
Q3 2022 Nov 10, 2022	SELL	$64.85 - $82.4 $1.02 Million - $1.29 Million	-15,670 Reduced 98.96%	164 $11,000
Q2 2022 Aug 10, 2022	SELL	$48.93 - $73.47 $2.07 Million - $3.1 Million	-42,236 Reduced 72.73%	15,834 $1.04 Million
Q1 2022 May 16, 2022	BUY	$51.99 - $72.11 $2.92 Million - $4.06 Million	56,237 Added 3068.03%	58,070 $3.86 Million
Q4 2021 Feb 14, 2022	SELL	$39.81 - $88.24 $855,516 - $1.9 Million	-21,490 Reduced 92.14%	1,833 $128,000
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $1.11 Million - $1.53 Million	21,315 Added 1061.5%	23,323 $1.22 Million
Q2 2021 Aug 13, 2021	SELL	$62.14 - $81.82 $2.2 Million - $2.89 Million	-35,379 Reduced 94.63%	2,008 $137,000
Q1 2021 May 12, 2021	BUY	$59.42 - $85.46 $1.38 Million - $1.99 Million	23,258 Added 164.61%	37,387 $2.88 Million
Q4 2020 Feb 11, 2021	BUY	$40.64 - $61.38 $89,082 - $134,544	2,192 Added 18.36%	14,129 $848,000
Q3 2020 Nov 12, 2020	BUY	$37.76 - $48.49 $440,508 - $565,684	11,666 Added 4304.8%	11,937 $514,000
Q2 2020 Jul 31, 2020	SELL	$37.03 - $60.0 $612,439 - $992,340	-16,539 Reduced 98.39%	271 $11,000
Q1 2020 May 01, 2020	BUY	$35.02 - $65.64 $197,372 - $369,947	5,636 Added 50.44%	16,810 $727,000
Q4 2019 Feb 14, 2020	SELL	$33.17 - $65.23 $709,638 - $1.4 Million	-21,394 Reduced 65.69%	11,174 $619,000
Q3 2019 Nov 14, 2019	BUY	$34.72 - $51.3 $1.11 Million - $1.63 Million	31,843 Added 4392.14%	32,568 $1.13 Million
Q2 2019 Aug 14, 2019	BUY	$27.2 - $41.2 $19,720 - $29,870	725 New	725 $29,000
Q1 2019 May 14, 2019	SELL	$19.86 - $32.9 $13,405 - $22,207	-675 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$15.03 - $25.38 $10,145 - $17,131	675 New	675 $14,000
Q4 2017 Feb 14, 2018	SELL	$8.19 - $11.19 $20,982 - $28,668	-2,562 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$9.75 - $10.64 $24,979 - $27,259	2,562	2,562 $26,000

Others Institutions Holding KRYS

# of Institutions

325

Shares Held

25M

Call Options Held

241K

Put Options Held

625K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $5.29B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account